The Department of Health and Human Services (HHS) is laying off certain employees that were notified months ago of the ...

Zimmer Biomet inked a $177 million deal to purchase Monogram Technologies, developer of a hands-free robotic surgery system ...

After 45 years at Henry Schein, including more than three decades as its CEO, Stanley Bergman has announced plans to retire ...

Days after JCR Pharmaceuticals signed a deal with AstraZeneca’s rare disease unit, the Japanese biopharma has secured a ...

The late-stage readout suggests that HRS9531 can hold its own against Eli Lilly’s blockbuster GLP-1/GIP agonist Zepbound, ...

The PD-1xVEGF dealmaking wave that has captivated Western pharma companies is now surging within China. | Sino Biopharm said it will pay up to $951 million to acquire LaNova Medicines, which has ...

Sellas Life Sciences’ investigational CDK9 inhibitor has scored in a midstage acute myeloid leukemia (AML) study, demonstrating an overall response rate (ORR) more than double the 20% goal.